AbbVie, the makers of Botox, raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq.

AbbVie's forecast raise comes on the back of the European Union's framework trade deal with the United States, under which all EU-produced pharmaceuticals entering the US will be subject to a 15% tariff. 

Already a subscriber? Sign in

You have reached your article limit.

Take us with you this summer

Annual €130 €65

Best value

Monthly €12€6 / month

Subscribe

Introductory offer. Annual billed once for first year. Monthly (discount first 3 months) billed monthly, then €12 / month. Ts&Cs apply.